EP3615079A4 - Stabile cannabinoidformulierungen - Google Patents

Stabile cannabinoidformulierungen Download PDF

Info

Publication number
EP3615079A4
EP3615079A4 EP17907335.8A EP17907335A EP3615079A4 EP 3615079 A4 EP3615079 A4 EP 3615079A4 EP 17907335 A EP17907335 A EP 17907335A EP 3615079 A4 EP3615079 A4 EP 3615079A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoid formulations
stable cannabinoid
stable
formulations
cannabinoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP17907335.8A
Other languages
English (en)
French (fr)
Other versions
EP3615079A1 (de
EP3615079C0 (de
EP3615079B1 (de
Inventor
Kiran Kumar VANGARA
Huaguang Li
Ningxin YAN
Hung Q. Nguyen
Venkat R. Goskonda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fresh Cut Development LLC
Original Assignee
Fresh Cut Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/499,178 external-priority patent/US12544389B2/en
Application filed by Fresh Cut Development LLC filed Critical Fresh Cut Development LLC
Priority to EP25152261.1A priority Critical patent/EP4516355A3/de
Publication of EP3615079A1 publication Critical patent/EP3615079A1/de
Publication of EP3615079A4 publication Critical patent/EP3615079A4/de
Application granted granted Critical
Publication of EP3615079C0 publication Critical patent/EP3615079C0/de
Publication of EP3615079B1 publication Critical patent/EP3615079B1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP17907335.8A 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen Active EP3615079B1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP25152261.1A EP4516355A3 (de) 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/499,178 US12544389B2 (en) 2014-05-29 2017-04-27 Stable cannabinoid formulations
PCT/US2017/052897 WO2018200024A1 (en) 2017-04-27 2017-09-22 Stable cannabinoid formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP25152261.1A Division EP4516355A3 (de) 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen

Publications (4)

Publication Number Publication Date
EP3615079A1 EP3615079A1 (de) 2020-03-04
EP3615079A4 true EP3615079A4 (de) 2020-09-23
EP3615079C0 EP3615079C0 (de) 2025-02-12
EP3615079B1 EP3615079B1 (de) 2025-02-12

Family

ID=63920361

Family Applications (2)

Application Number Title Priority Date Filing Date
EP25152261.1A Pending EP4516355A3 (de) 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen
EP17907335.8A Active EP3615079B1 (de) 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP25152261.1A Pending EP4516355A3 (de) 2017-04-27 2017-09-22 Stabile cannabinoidformulierungen

Country Status (4)

Country Link
EP (2) EP4516355A3 (de)
JP (5) JP2020517727A (de)
CA (1) CA3062814C (de)
WO (1) WO2018200024A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12544389B2 (en) 2014-05-29 2026-02-10 Fresh Cut Development, Llc Stable cannabinoid formulations
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CA3062814C (en) * 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
CN117695226A (zh) 2018-12-11 2024-03-15 迪斯拉普申实验室公司 用于递送治疗剂的组合物及其使用方法和制备方法
GB2584140A (en) * 2019-05-23 2020-11-25 Gw Res Ltd Use of cannabidiol in the treatment of epileptic spasms
US20220347118A1 (en) * 2019-09-09 2022-11-03 Cardiol Therapeutics Inc. Stable medicinal cannabidiol compositions
GB2588461A (en) * 2019-10-25 2021-04-28 Gw Res Ltd Use of cannabidiol preparations in the treatment of absence epilepsy
US20220401380A1 (en) * 2019-10-25 2022-12-22 Cardiol Therapeutics Inc. Cannabidiol compositions for use in treating heart conditions
TW202231192A (zh) * 2020-09-24 2022-08-16 英商尼可創業貿易有限公司 包裝調配物
JP2023546649A (ja) * 2020-09-24 2023-11-07 ニコベンチャーズ トレーディング リミテッド 製剤
JP2024528569A (ja) * 2021-07-13 2024-07-30 イーピーエム（アイピー）， インコーポレイテッド プラダー・ウィリー症候群を治療するためのカンナビジオール酸エステル
US20250025482A1 (en) * 2021-07-28 2025-01-23 GW Research Limited Use of cannabidiol in the treatment of epilepsy
AU2023361756A1 (en) * 2022-10-12 2025-05-22 Leiutis Pharmaceuticals Llp Novel liquid oral formulations of cannabidiol
CN115887426A (zh) * 2022-11-18 2023-04-04 中国人民解放军军事科学院军事医学研究院 大麻二酚在制备核辐射损伤后骨髓恢复药物中的应用
CN116444351A (zh) * 2022-11-18 2023-07-18 中国人民解放军军事科学院军事医学研究院 一种核辐射损伤中对小肠有保护作用的天然小分子化合物
CN116172988A (zh) * 2022-11-18 2023-05-30 中国人民解放军军事科学院军事医学研究院 大麻二酚用于制备急性放射病的药物的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150343071A1 (en) * 2014-05-29 2015-12-03 Insys Pharma, Inc. Stable cannabinoid formulations
US20160271252A1 (en) * 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2576505A1 (en) * 2004-08-03 2006-02-16 Orexigen Therapeutics, Inc. Combination of bupropion and a second compound for affecting weight loss
MX2008006550A (es) * 2005-11-23 2008-09-23 Ironwood Pharmaceuticals Inc Metodos y composiciones para el tratamiento de trastornos gastrointestinales.
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
WO2011057199A1 (en) * 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
WO2011150338A1 (en) * 2010-05-27 2011-12-01 Zafgen Corporation Methods of treating obesity
US11331279B2 (en) * 2014-05-29 2022-05-17 Radius Pharmaceuticals, Inc. Stable cannabinoid formulations
CA3062814C (en) * 2017-04-27 2023-11-14 Insys Development Company, Inc. Stable cannabinoid formulations

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150343071A1 (en) * 2014-05-29 2015-12-03 Insys Pharma, Inc. Stable cannabinoid formulations
US20160271252A1 (en) * 2014-05-29 2016-09-22 Insys Development Company, Inc. Stable cannabinoid formulations
US20160367496A1 (en) * 2014-05-29 2016-12-22 Insys Development Company, Inc. Stable cannabinoid formulations
WO2016191651A1 (en) * 2015-05-28 2016-12-01 Insys Development Company, Inc. Stable cannabinoid formulations

Also Published As

Publication number Publication date
JP2024161363A (ja) 2024-11-19
JP2020517727A (ja) 2020-06-18
JP2025118786A (ja) 2025-08-13
WO2018200024A1 (en) 2018-11-01
EP3615079A1 (de) 2020-03-04
EP3615079C0 (de) 2025-02-12
JP2022130390A (ja) 2022-09-06
EP4516355A3 (de) 2025-05-28
JP2025118787A (ja) 2025-08-13
CA3062814A1 (en) 2018-11-01
EP4516355A2 (de) 2025-03-05
CA3062814C (en) 2023-11-14
EP3615079B1 (de) 2025-02-12

Similar Documents

Publication Publication Date Title
IL289084A (en) Cannabinoid formulations
EP3615079A4 (de) Stabile cannabinoidformulierungen
DK3302437T3 (da) Stabile cannabinoidformuleringer
IL288423A (en) Cannabinoid formulations
IL268697A (en) Formulations
DK3688162T3 (da) Formuleringer
EP3148589C0 (de) Stabile cannabinoidformulierungen
EP3703672A4 (de) Cannabinoidformulierungen
EP3642262A4 (de) Härtbare polyimide
MA50657A (fr) Formulations de niraparib
EP3641726C0 (de) Cannabinoid-beutel
EP3574547C0 (de) Wellenleiteranordnung
EP3462885A4 (de) Stabile cannabinoidformulierungen
EP3645897A4 (de) Lager
EP3367997A4 (de) Neuartige okklusive formulierungen
EP3646858A4 (de) Verkapselte formulierungen
EP3364945C0 (de) Feste formulierungen
DK3651736T3 (da) Langtidsvirkende formuleringer
EP3612761C0 (de) Koppler
EP3585412A4 (de) Stabile peptidzusammensetzungen
IT201700051935A1 (it) Dispositivo laser
EP3437579C0 (de) Kryochirurgisches instrument
HUE063178T2 (hu) Kopanlizib formulációi
EP3683000A4 (de) Laservorrichtung
IL272167A (en) Hemopexin formulations

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191126

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FRESH CUT DEVELOPMENT, LLC

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FRESH CUT DEVELOPMENT, LLC

A4 Supplementary search report drawn up and despatched

Effective date: 20200826

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 47/10 20170101ALI20200820BHEP

Ipc: A61P 3/00 20060101ALI20200820BHEP

Ipc: A61K 47/14 20170101AFI20200820BHEP

Ipc: A61P 25/08 20060101ALI20200820BHEP

Ipc: A61K 47/44 20170101ALI20200820BHEP

Ipc: A61P 3/04 20060101ALI20200820BHEP

Ipc: A61K 31/05 20060101ALI20200820BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220802

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20230307

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: RADIUS PHARMACEUTICALS, INC.

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20231220

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20240830

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: FRESH CUT DEVELOPMENT, LLC

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602017087772

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

U01 Request for unitary effect filed

Effective date: 20250312

P04 Withdrawal of opt-out of the competence of the unified patent court (upc) registered

Free format text: CASE NUMBER: APP_13438/2025

Effective date: 20250318

U07 Unitary effect registered

Designated state(s): AT BE BG DE DK EE FI FR IT LT LU LV MT NL PT RO SE SI

Effective date: 20250321

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250612

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250512

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250513

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

U20 Renewal fee for the european patent with unitary effect paid

Year of fee payment: 9

Effective date: 20250902

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20250704

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20250212

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20251113